Organic Letters
Letter
910. (b) Le Bourdonnec, B.; Goodman, A. J.; Michaut, M.; Ye, H.;
Graczyk, T. M.; Belanger, S.; Herbertz, T.; Yap, G. P. A.; DeHaven, R.
N.; Dolle, R. E. J. Med. Chem. 2006, 49, 7278−7289. (c) Boja, P.; Won,
S. W.; Suh, D. H.; Chu, J.; Park, W. K.; Lim, H. J. Korean Chem. Soc.
2006, 27, 1371−1376. (d) Castro, N. G.; Costa, R. S.; Pimentel, L. S.
B.; Danuello, A.; Romeiro, N. C.; Viegas, C., Jr.; Barreiro, E. J.; Fraga, C.
A. M.; Bolzani, V. S.; Rocha, M. S. Eur. J. Pharmacol. 2008, 580, 339−
349.
Scheme 5. Ring Expansion of (Trifluoromethyl)prolinol 4
with Carbanion
(3) (a) De Kimpe, N.; Boelens, M.; Piqueur, J.; Baele, J. Tetrahedron
Lett. 1994, 1925−1928. (b) De Kimpe, N.; Boelens, M.; Contreras, J.
Tetrahedron Lett. 1996, 3171−3174. For reviews, see: (c) Gomez
Pardo, D.; Cossy, J. Chemtracts 2002, 15, 579−605. (d) Cossy, J.;
́
Gomez Pardo, D.; Dumas, C.; Mirguet, O.; Dechamps, I.; Metro, T.-X.;
Burger, B.; Roudeau, R.; Appenzeller, J.; Cochi, A. Chirality 2009, 21,
850−856. (e) Cochi, A.; Gomez Pardo, D.; Cossy, J. Eur. J. Org. Chem.
2012, 2023−2040. (f) Gomez Pardo, D.; Cossy, J. Chem.Eur. J. 2014,
20, 4516−4525 and references cited therein.
(4) (a) Cossy, J.; Dumas, C.; Gomez Pardo, D. Synlett 1997, 905−
906. (b) Cossy, J.; Dumas, C.; Gomez Pardo, D. Bioorg. Med. Chem.
Scheme 6. Ring Expansion of (Trifluoromethyl)pyrrolidinol
5 with Carbanion
́
Lett. 1997, 7, 1343−1344. (c) Dechamps, I.; Gomez Pardo, D.;
Karoyan, P.; Cossy, J. Synlett 2005, 1170−1172. (d) Roudeau, R.;
Gomez Pardo, D.; Cossy, J. Tetrahedron 2006, 62, 2388−2394.
(e) Dec
́
hamps, I.; Gomez Pardo, D.; Cossy, J. Tetrahedron 2007, 63,
9082−9091. (f) Rives, A.; Gen
́
isson, Y.; Faugeroux, V.; Saffon, N.;
Baltas, M. Synthesis 2009, 3251−3258. (g) In, J.; Lee, S.; Kwon, Y.; Kim,
S. Chem.Eur. J. 2014, 20, 17433−17442.
(5) (a) Heindl, C.; Hubner, H.; Gmeiner, P. Tetrahedron: Asymmetry
̈
2003, 14, 3153−3172. (b) Davis, F. A.; Deng, J. Tetrahedron 2004, 60,
5111−5115. (c) Cochi, A.; Gomez Pardo, D.; Cossy, J. Org. Lett. 2011,
13, 4442−4445.
(6) For a theoretical rationalization of the ring opening of monocyclic
aziridinium ions with halides, see: (a) D’hooghe, M.; Catak, S.;
Stankovic, S.; Waroquier, M.; Kim, Y.; Ha, H.-J.; Van Speybroeck, V.;
De Kimpe, N. Eur. J. Org. Chem. 2010, 4920−4931. For specific
examples of the opening of bicyclic aziridinium ions with DAST, see:
depending on whether one uses L- or D-proline as the starting
material. This access to 3-substituted 2-(trifluoromethyl)-
piperidines should be of interest for medicinal chemists.
(b) Dec
4224−4234. (c) Dec
́
hamps, I.; Gomez Pardo, D.; Cossy, J. Eur. J. Org. Chem. 2007,
hamps, I.; Gomez Pardo, D.; Cossy, J. Synlett
́
ASSOCIATED CONTENT
* Supporting Information
2007, 2, 263−267. (d) Anxionnat, B.; Robert, B.; George, P.; Ricci, G.;
Perrin, M.-A.; Gomez Pardo, D.; Cossy, J. J. Org. Chem. 2012, 77,
6087−6099.
■
S
Experimental procedures, characterization data for all com-
pounds, and copies of 1H and 13C NMR spectra for all
compounds as well as experimental chromatograms of
enantiomeric excess for the products concerned. The Support-
ing Information is available free of charge on the ACS
(7) Charette, A. B.; Scott, B. D. J. Org. Lett. 2011, 13, 3830−3833.
(8) (a) Katagiri, T.; Takahashi, M.; Fujiwara, Y.; Ihara, H.; Uneyama,
́
K. J. Org. Chem. 1999, 64, 7323−7329. (b) Metro, T.-X.; Duthion, B.;
Gomez Pardo, D.; Cossy, J. Chem. Soc. Rev. 2010, 39, 89−102. (c) De
Kimpe, N.; Van Nguyen, T.; Thi, T. A. D.; Nguyen, V. D.; Verniest, G.;
D’Hooghe, M.; Kenis, S. Org. Biomol. Chem. 2011, 9, 7217−7223.
(d) Stankovic, S.; D’hooghe, M.; Catak, S.; Eum, H.; Waroquier, M.;
Van Speybroeck, V.; De Kimpe, N.; Ha, H.-J. Chem. Soc. Rev. 2012, 41,
643−665. (e) Moens, M.; De Kimpe, N.; D’hooghe, M. J. Org. Chem.
2014, 79, 5558−5568.
AUTHOR INFORMATION
Corresponding Authors
■
(9) Bejjani, J.; Chemla, F.; Audouin, M. J. Org. Chem. 2003, 68, 9747−
9752.
(10) Xiu-Hua, X.; Qiu, X. L.; Qing, F. L. Tetrahedron 2008, 64, 7353−
7361.
(11) See the Supporting Information for SFC and chiral HPLC
Notes
The authors declare no competing financial interest.
conditions used.
ACKNOWLEDGMENTS
(12) Mino, T.; Saito, A.; Tanaka, Y.; Hasegawa, S.; Sata, Y.; Sakamoto,
M.; Fujita, T. J. Org. Chem. 2005, 70, 1937−1940.
■
GlaxoSmithkline is acknowledged for a grant to S. R. and for
financial support. Diverchim is acknowledged for its help for the
determination of the enantiomeric excess.
́ ́
(13) (a) Spanedda, M. V.; Crousse, B.; Begue, J. P.; Bonnet-Delpon,
D. Tetrahedron Lett. 2004, 45, 5023−5025. (b) Erxleben, N. D.;
Kedziora, G. S. Theor. Chem. Acc. 2014, 133, No. 1491.
(14) Marino, J. P.; Jaen
́
, J. C. J. Am. Chem. Soc. 1982, 104, 3165−3172.
REFERENCES
■
(1) (a) Kirk, K. L. J. Fluorine Chem. 2006, 127, 1013−1029.
(b) Hagmann, W. K. J. Med. Chem. 2008, 51, 4360−4369. (b) Orliac,
A.; Routier, J.; Burgat Charvillon, F.; Sauer, W. H. B.; Bombrun, A.;
Kulkarni, S. S.; Gomez Pardo, D.; Cossy, J. Chem.Eur. J. 2014, 20,
3813−3824.
(2) (a) Viegas, C., Jr.; Bolzani, V. S.; Furlan, M.; Barreiro, E. J.; Young,
M. C. M.; Tomazela, D.; Eberlin, M. N. J. Nat. Prod. 2004, 67, 908−
D
Org. Lett. XXXX, XXX, XXX−XXX